A Pilot Study of Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
Phase of Trial: Phase II
Latest Information Update: 30 Aug 2017
At a glance
- Drugs Pembrolizumab (Primary) ; Irinotecan; Paclitaxel
- Indications Neuroendocrine carcinoma
- Focus Therapeutic Use
- 19 Jul 2017 Status changed from not yet recruiting to recruiting.
- 05 May 2017 New trial record
- 04 May 2017 Planned End Date changed from 1 May 2020 to 1 Jun 2020.